CN105683162A - N-(4-氯-2-羟基-3((3s)-3-哌啶基磺酰基)苯基)-n’-(3-氟-2-甲基苯基)脲的氢溴酸盐 - Google Patents

N-(4-氯-2-羟基-3((3s)-3-哌啶基磺酰基)苯基)-n’-(3-氟-2-甲基苯基)脲的氢溴酸盐 Download PDF

Info

Publication number
CN105683162A
CN105683162A CN201480061455.2A CN201480061455A CN105683162A CN 105683162 A CN105683162 A CN 105683162A CN 201480061455 A CN201480061455 A CN 201480061455A CN 105683162 A CN105683162 A CN 105683162A
Authority
CN
China
Prior art keywords
disease
situation
compound
compounds
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480061455.2A
Other languages
English (en)
Chinese (zh)
Inventor
F.D.桑德森
S.M.瓦兰斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of CN105683162A publication Critical patent/CN105683162A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CN201480061455.2A 2013-11-13 2014-11-11 N-(4-氯-2-羟基-3((3s)-3-哌啶基磺酰基)苯基)-n’-(3-氟-2-甲基苯基)脲的氢溴酸盐 Pending CN105683162A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1320021.7 2013-11-13
GBGB1320021.7A GB201320021D0 (en) 2013-11-13 2013-11-13 Novel Compounds
PCT/EP2014/074222 WO2015071235A1 (en) 2013-11-13 2014-11-11 Hydrobromide salt ofn-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea

Publications (1)

Publication Number Publication Date
CN105683162A true CN105683162A (zh) 2016-06-15

Family

ID=49818555

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480061455.2A Pending CN105683162A (zh) 2013-11-13 2014-11-11 N-(4-氯-2-羟基-3((3s)-3-哌啶基磺酰基)苯基)-n’-(3-氟-2-甲基苯基)脲的氢溴酸盐

Country Status (24)

Country Link
US (3) US9809540B2 (https=)
EP (1) EP3068763B1 (https=)
JP (1) JP6401265B2 (https=)
KR (1) KR20160083950A (https=)
CN (1) CN105683162A (https=)
AU (1) AU2014350334B2 (https=)
BR (1) BR112016010409A8 (https=)
CA (1) CA2929907A1 (https=)
CY (1) CY1121581T1 (https=)
DK (1) DK3068763T3 (https=)
ES (1) ES2714721T3 (https=)
GB (1) GB201320021D0 (https=)
HR (1) HRP20190449T1 (https=)
HU (1) HUE041873T2 (https=)
LT (1) LT3068763T (https=)
ME (1) ME03328B (https=)
PL (1) PL3068763T3 (https=)
PT (1) PT3068763T (https=)
RS (1) RS58382B1 (https=)
RU (1) RU2685408C1 (https=)
SI (1) SI3068763T1 (https=)
SM (1) SMT201900156T1 (https=)
TR (1) TR201902981T4 (https=)
WO (1) WO2015071235A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170100385A1 (en) * 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
BR112018011138A2 (pt) * 2015-11-30 2018-11-21 Glaxosmithkline Intellectual Property (No. formulações para administração intravenosa
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101472477A (zh) * 2006-04-21 2009-07-01 史密丝克莱恩比彻姆公司 Il-8受体拮抗剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101472477A (zh) * 2006-04-21 2009-07-01 史密丝克莱恩比彻姆公司 Il-8受体拮抗剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JACKIE C.BLOOMER，ET AL.: "Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling", 《BR J CLIN PHARMACOL》 *
STEPHEN M. BERGE，ET AL.: "Pharmaceutical Salts", 《JOURNAL OF PHARMACEUTICAL SCIENCES》 *

Also Published As

Publication number Publication date
TR201902981T4 (tr) 2019-03-21
US20180079722A1 (en) 2018-03-22
RU2685408C1 (ru) 2019-04-18
RS58382B1 (sr) 2019-04-30
RU2016116955A (ru) 2017-12-19
EP3068763A1 (en) 2016-09-21
LT3068763T (lt) 2019-03-12
AU2014350334B2 (en) 2017-08-10
PT3068763T (pt) 2019-03-20
HRP20190449T1 (hr) 2019-04-19
CY1121581T1 (el) 2020-05-29
JP2016537344A (ja) 2016-12-01
US20190112269A1 (en) 2019-04-18
GB201320021D0 (en) 2013-12-25
US9809540B2 (en) 2017-11-07
HUE041873T2 (hu) 2019-05-28
BR112016010409A8 (pt) 2020-04-22
EP3068763B1 (en) 2018-12-19
KR20160083950A (ko) 2016-07-12
SI3068763T1 (sl) 2019-04-30
ME03328B (me) 2019-10-20
US10604485B2 (en) 2020-03-31
CA2929907A1 (en) 2015-05-21
DK3068763T3 (en) 2019-03-18
ES2714721T3 (es) 2019-05-29
PL3068763T3 (pl) 2019-05-31
WO2015071235A1 (en) 2015-05-21
SMT201900156T1 (it) 2019-05-10
JP6401265B2 (ja) 2018-10-10
AU2014350334A1 (en) 2016-06-02
US20160264525A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
JP7745892B2 (ja) Ｎ４－ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
CN100444839C (zh) 式(i)化合物在制备治疗化学激活物中介的疾病的药物中的应用
TW200918063A (en) Method of treating CXCR3 mediated diseases using heterocyclic substituted piperazines
TW200902005A (en) Peripheral opioid receptor antagonists and uses thereof
CN109415339A (zh) N-[2-(3-羟基-3-甲基丁基)-6-(2-羟基丙-2-基)-2h-吲唑-5-基]-6-(三氟甲基)吡啶-2-甲酰胺的结晶形式
CN114787155A (zh) 药物化合物
US10604485B2 (en) Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N′-(3-Fluoro-2-methylphenyl)urea
JPH10510538A (ja) 新規化合物
JP7667764B2 (ja) 線維症疾患の治療及び／又は予防用アミノナフトキノン化合物
JP2025507623A (ja) （ｓ）－１－（（２’，６－ビス（ジフルオロメチル）－［２，４’－ビピリジン］－５－イル）オキシ）－２，４－ジメチルペンタン－２－アミン及びその塩の固体形態
CN115279345A (zh) 8-氯-n-(4-(三氟甲氧基)苯基)喹啉-2-胺的无定形固体分散体
TW490465B (en) Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof
JP7597710B2 (ja) 置換インドール二量体の化合物
JP2009507921A (ja) ピペラジン化合物のグルクロン酸塩
CZ2003140A3 (cs) Nová forma (R)-N-[5-methyl-8-(4-methylpiperazin-l-yl)-1,2,3,4-tetrahydro-2-naftyl]-4-morfolinobenzamidu
TW580499B (en) Carbapenem compound, use thereof and intermediate compound therefor
JP2000500454A (ja) 血液調節化合物
CN108658843B (zh) 乙酰苄胺哌啶酰胺类衍生物及其作为脑神经保护剂的应用
WO2006074919A2 (de) 3 -AMINO- 6-ARYL (BZW.6-HETEROARYL) -THIENO [2 , 3-B] PYRIDIN-2-CARBONSÄUREAMIDE, DIESE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN UND IHRE VERWENDUNG ALS INHIBITOREN DER TNFα-FREISETZUNG
DE69712626T2 (de) Methansulfonatsalz eines arylpiperazinderivat von tryptamin und seine solvate zur pharmazeutische verwendung
US11179400B2 (en) Heterocyclic compounds as RSV inhibitors
CN1308629A (zh) 粒度减小形式的1－(6－氯萘－2－基磺酰基)－4－[4－(4－吡啶基)苯甲酰基]哌嗪
HK40129081A (zh) N4-羟基胞苷和衍生物及其相关的抗病毒用途
TW200811131A (en) Piperidine derivatives as CXCR3 receptor antagonists
CN106432244A (zh) 一种hedgehog信号通路抑制剂的结晶形式及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160615

RJ01 Rejection of invention patent application after publication